This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Spectrum Pharmaceuticals Highlights 19 Abstracts At The 54th Annual Meeting Of The American Society Of Hematology (ASH), Atlanta, Georgia, December 8-11, 2012

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data at the 54th Annual Meeting of the American Society of Hematology (ASH), being held in Atlanta, Georgia, from December 8-11, 2012. The presentations include two oral presentations and 10 poster presentations for ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use, three poster presentations for FOLOTYN® (pralatrexate injection), and four poster presentations for belinostat, a novel histone deacetylase (HDAC) inhibitor.

“Nearly 20 presentations at ASH will feature clinical and scientific data for Spectrum’s commercial products, ZEVALIN and FOLOTYN, as well as our late-stage drug candidate, belinostat,” said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. “The ZEVALIN-related abstracts demonstrate its use in a multitude of diverse settings and potential indications in which this product is being tested, including transplantation, its use in elderly patients, in frontline treatment and in the treatment of relapsed/refractory disease, as well as in new drug combinations. The FOLOTYN-related abstracts include presentations on new, synergistic combinations with other approved agents and in difficult-to-treat indications, such as HTLV-1-induced leukemia/lymphoma, while belinostat-related presentations are studying new combinations and indications, such as in refractory AML/MDS, as well as research on this promising drug candidate’s mechanism of action.”

For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference Web site at https://ash.confex.com/ash/2012/webprogram/start.html.

The following are key ZEVALIN-related abstracts being presented at the ASH meeting:

                 
Abstract #   Type   Title   First Author   Date/Time

Location

1978   Poster   Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial   Briones   Saturday, Dec. 8

5:30 PM-7:30 PM

 

Hall B1-B2

2742   Poster   RIT with 90Y Ibritumomab Tiuxetan in Patients with Non-Hodgkin Lymphoma Over 65 Years   Andrade   Sunday, Dec. 9,

6:00 PM-8:00 PM

 

Hall B1-B2

2687   Poster   A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402)   Witzig   Sunday, Dec. 9,

6:00 PM-8:00 PM

 

Hall B1-B2

2726   Poster   90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients   Terriou   Sunday, Dec. 9,

6:00 PM-8:00 PM

 

Hall B1-B2

2729   Poster   Rituximab-PECC Induction Followed by 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study   Lugtenburg   Sunday, Dec 9,

6:00 PM-8:00 PM

 

Hall B1-B2

2753   Poster   Phase I Trial of Combination Therapy with 90y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma, Final Report   Borghaei   Sunday, Dec. 9,

6:00 PM-8:00 PM

 

Hall B1-B2

3019   Poster   Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma   Derenzini   Sunday, Dec. 9,

6:00 PM-8:00 PM

 

Hall B1-B2

747   Oral   Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin   Kolstad   Monday, Dec. 10, 5:00 PM

 

B312-B313a

3657   Poster   Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of "Fol-Brite"   Lansigan   Monday, Dec. 10,

6:00 PM-8:00 PM

 

Hall B1-B2

3648   Poster   FDG-PET/CT Early After 90Y-Ibritumomab Tiuxetan Therapy Predicts Outcome in Relapsed or Refractory Indolent B-Cell Lymphoma   Okada   Monday, Dec. 10,

6:00 PM-8:00 PM

 

Hall B1-B2

3681   Poster   Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Υ-Radioimmunotherapy and Maintenance Rituximab   Berinstein   Monday, Dec. 10,

6:00 PM-8:00 PM

 

Hall B1-B2

812   Oral   Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma   Fruchart   Monday, Dec. 10

6:30 PM

 

B312-B313a

       

The following are key FOLOTYN-related abstracts being presented at the ASH meeting:

                 
Abstract #   Type   Title   First Author   Location
2735   Poster   Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience   Lunning   Sunday, Dec. 9,

6:00 PM-8:00 PM

 

Hall B1-B2

2758   Poster   Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate   Jain   Sunday, Dec. 9,

6:00 PM-8:00 PM

 

Hall B1-B2

3660   Poster   Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma   Parker   Monday, Dec. 10,

6:00 PM-8:00 PM

 

Hall B1-B2

       

The following are key belinostat-related abstracts being presented at the ASH conference:

                 
Abstract #   Type   Title   First Author   Location
1359   Poster   Mechanisms of Sensitivity and Resistance to Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma   Tula-Sanchez   Saturday, Dec. 8,

5:30 PM-7:30 PM

 

Hall B1-B2

2725   Poster   Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease   Amengual   Sunday, Dec. 9,

6:00 PM-8:00 PM

 

Hall B1-B2

3588   Poster   Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update   Holkova   Monday, Dec. 10,

6:00 PM-8:00 PM

 

Hall B1-B2

3891   Poster   Inhibition of Histone Deacetylase Activity Compromises Homologous Recombination Repair and Increases Sensitivity of Chemo-Resistant Chronic Lymphocytic Leukemia Cells to Olaparib   Agathanggelou   Monday, Dec. 10,

6:00 PM-8:00 PM

 

Hall B1-B2

       

About Non-Hodgkin's Lymphoma

According to the National Cancer Institute ( www.cancer.gov), there are expected to be 70,130 new cases of non-Hodgkin's lymphoma diagnosed and approximately 18,940 deaths in the United States in 2012. Non-Hodgkin's lymphoma is defined as any of a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin's lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of non-Hodgkin's lymphoma. These types can be divided into aggressive (fast-growing) and indolent or low grade (slow-growing) types, and they can be formed from either B-cells or T-cells. Prognosis and treatment depend on the stage and type of disease.

About ZEVALIN® and the ZEVALIN Therapeutic Regimen

ZEVALIN (ibritumomab tiuxetan) injection for intravenous use, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma who achieve a partial or complete response to first-line chemotherapy.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,979.13 +59.54 0.35%
S&P 500 1,986.51 +4.91 0.25%
NASDAQ 4,526.4820 -1.0320 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs